Heterozygous IDH1/2 mutations have been predominantly detected in gliomas, with an accumulation of D-2-HG in tumor tissue [9], and in acute myeloid leukemia (AML), with high serum levels of D-2-HG [10,11]. Here, IDH1 is linked to neoplasm.